Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 3/20 | 0.71 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.71 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.51 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 3/20 | 0.46 |
| ▸ | ACACA | Q13085 | 2/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6732078 | 0.96 | KCNQ3 (0.71) | KCNQ3KCNQ2KCNQ4KCNQ5SCN9A | |
| SCHEMBL6736357 | 0.89 | KCNQ3 (0.67) | KCNQ3KCNQ2KCNQ4KCNQ5SCN9A | |
| SCHEMBL6736355 | 0.89 | KCNQ3 (0.67) | KCNQ3KCNQ2KCNQ4KCNQ5SCN9A | |
| SCHEMBL6738385 | 0.85 | KCNQ3 (0.78) | KCNQ3KCNQ2KCNQ4KCNQ5SCN9A | |
| SCHEMBL6732121 | 0.85 | KCNQ3 (0.78) | KCNQ3KCNQ2KCNQ4KCNQ5SCN9A | |
| SCHEMBL6741277 | 0.84 | KCNQ3 (0.85) | KCNQ3KCNQ2KCNQ4KCNQ5SCN9A | |
| SCHEMBL6741274 | 0.84 | KCNQ3 (0.85) | KCNQ3KCNQ2KCNQ4KCNQ5SCN9A | |
| SCHEMBL6741227 | 0.84 | KCNQ3 (0.85) | KCNQ3KCNQ2KCNQ4KCNQ5SCN9A | |
| SCHEMBL6732183 | 0.84 | KCNQ3 (0.80) | KCNQ3KCNQ2KCNQ4KCNQ5SCN9A | |
| SCHEMBL6732185 | 0.84 | KCNQ3 (0.80) | KCNQ3KCNQ2KCNQ4KCNQ5SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235830-A1 | Substituted cyclohexane derivatives and the use thereof in medicaments for treating cardiovascular diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235830-A1 | Substituted cyclohexane derivatives and the use thereof in medicaments for treating cardiovascular diseases | CYP46A1, REN, CYP11B2 | KCNQ3 3634/4885KCNQ2 3637/4885KCNQ4 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.